It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Despite the wealth of evidence demonstrating the efficacy of treatment intensification beyond androgen-deprivation therapy (ADT) among patients with de novo metastatic castration-sensitive prostate cancer (mCSPC), little is known of its real-world use. This study examined the real-world uptake of ADT treatment intensification among older men in a large Canadian province.
Methods
We performed a retrospective population-based cohort study using province-wide linked administrative data in Ontario, Canada. Patients 66 years of age and older with de novo mCSPC were included and their treatment with conventional ADT-based regimens, ADT plus next-generation androgen receptor axis–targeted therapy, and ADT plus docetaxel were identified and stratified by time.
Results
From 2014 to 2019, 3556 patients were identified with de novo mCSPC. Most patients (n = 2794 [78.6%]) were treated with a conventional ADT regimen, whereas 399 (11.2%) patients received ADT intensification with docetaxel and 52 (1.5%) patients received abiraterone acetate plus prednisone. In a time-stratified analysis of ADT intensification before and after the pivotal AA+P trial (LATITUDE), AA+P uptake increased from 0.5% to 3.0%, whereas docetaxel use dropped from 12.0% to 10.0%. The median survival of the study population was 18 months (interquartile range = 10-31).
Conclusions
The majority of patients with de novo mCSPC are treated with ADT alone in the Canadian real-world setting, despite randomized clinical trial evidence of benefit with the use of ADT-intensified regimens. As ADT treatment intensification is substantially underused, better understanding of the barriers to treatment and targeted education to address them are needed.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
2 Division of Radiation Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
3 Division of Urology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
4 Department of Surgery, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada
5 Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
6 Department of Oncology, McGill University, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada
7 Department of Surgery, Southern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada
8 Division of Medical Oncology, London Regional Cancer Program, London, ON, Canada
9 Radiation Oncology Department, Jewish General Hospital, McGill University, Montreal, QC, Canada
10 BC Cancer Agency, University of British Columbia, Surrey, BC, Canada
11 Genitourinary Oncology, Centre Hospitalier de l’Université de Montréal, University of Montreal, Montréal, QC, Canada
12 Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada
13 Medical Affairs, Janssen Inc, Toronto, ON, Canada
14 Institute of Urology, St Joseph’s Healthcare, McMaster University, Hamilton, ON, Canada